Skip to main content

Table 4 Sensitivity analysis

From: Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K

   Change in Outcome CER
Parameter Net Cost LYG QALY Cost/LYG Cost/QALY
Base values £2,066 0.32 0.37 £6,772 £5,609
Age (mean)      
46.5 years £2,531 0.34 0.45 £7,476 £5,589
82.5 years £718 0.14 0.12 £5,303 £5,804
Cost of complications      
+20% £1,973 0.32 0.37 £6,213 £5,357
-20% £2,159 0.32 0.37 £6,799 £5,861
Duration of disease before oral agent prescribed      
5 years £2,101 0.27 0.33 £7,680 £6,320
10 years £1,971 0.31 0.35 £6,260 £5,553
Utilities      
+20% £2,066 0.32 0.36 £6,506 £5,807
-20% £2,066 0.32 0.38 £6,506 £5,426
Race      
100% Caucasian £2,105 0.31 0.36 £6,686 £5,771
HbA1c level      
HbA1c before prescription = 9.4% £1,782 0.37 0.42 £4,784 £4,287
Metformin = 8.6%      
Combination = 7.9%      
HbA1c before prescription = 7.9% £2,184 0.28 0.34 £7,904 £6,516
Metformin = 7.1%      
Combination = 6.4%      
HbA1c upward drift      
Metformin = 1.5%; Combination = 0% £1,478 0.54 0.65 £2,761 £2,272
Metformin = 0%; Combination = 0% £2,307 0.28 0.31 £8,336 £7,338
HbA1c drift delay      
Metformin = 0 years; Combination = 1 year £1,987 0.35 0.41 £5,715 £4,870
Discount      
Cost = 3%; Benefit = 3% £2,420 0.26 0.30 £9,319 £8,058
Cost = 6%; Benefit = 6% £2,066 0.18 0.21 £11,369 £9,888
Cost = 6%; Benefit = 0% £2,066 0.39 0.46 £5,237 £4,500